Paul Hastings LLP advised Jasper Therapeutics, Inc., while DLA Piper advised the underwriters. Jasper Therapeutics, Inc. (Nasdaq: JSPR), a clinical-stage biotechnology company focused on developing novel…
Jasper Therapeutics’ $50 Million Common Stock Offering
![](https://globallegalchronicle.com/wp-content/uploads/2024/02/jasper-therapeutics-50-million-common-stock-offering_65dd81d9f01eb-480x360.jpeg)